TRIM28-dependent developmental heterogeneity determines cancer susceptibility through distinct epigenetic states

IF 28.5 1区 医学 Q1 ONCOLOGY Nature cancer Pub Date : 2025-01-24 DOI:10.1038/s43018-024-00900-3
Ilaria Panzeri, Luca Fagnocchi, Stefanos Apostle, Megan Tompkins, Emily Wolfrum, Zachary Madaj, Galen Hostetter, Yanqing Liu, Kristen Schaefer, Chih-Hsiang Yang, Alexis Bergsma, Anne Drougard, Erez Dror, PERMUTE, Darrell P. Chandler, Daniel Schramek, Timothy J. Triche Jr., John Andrew Pospisilik
{"title":"TRIM28-dependent developmental heterogeneity determines cancer susceptibility through distinct epigenetic states","authors":"Ilaria Panzeri, Luca Fagnocchi, Stefanos Apostle, Megan Tompkins, Emily Wolfrum, Zachary Madaj, Galen Hostetter, Yanqing Liu, Kristen Schaefer, Chih-Hsiang Yang, Alexis Bergsma, Anne Drougard, Erez Dror, PERMUTE, Darrell P. Chandler, Daniel Schramek, Timothy J. Triche Jr., John Andrew Pospisilik","doi":"10.1038/s43018-024-00900-3","DOIUrl":null,"url":null,"abstract":"Mutations in cancer risk genes increase susceptibility, but not all carriers develop cancer. Indeed, while DNA mutations are necessary drivers of cancer, only a small subset of mutated cells go on to cause the disease. To date, the mechanisms underlying individual cancer susceptibility remain unclear. Here, we took advantage of a unique mouse model of intrinsic developmental heterogeneity (Trim28+/D9) to investigate whether early-life epigenetic variation influences cancer susceptibility later in life. We found that heterozygosity of Trim28 is sufficient to generate two distinct early-life epigenetic states associated with differing cancer susceptibility. These developmentally primed states exhibit differential methylation patterns at typically silenced heterochromatin, detectable as early as 10 days of age. The differentially methylated loci are enriched for genes with known oncogenic potential, frequently mutated in human cancers and correlated with poor prognosis. This study provides genetic evidence that intrinsic developmental heterogeneity can prime individual, lifelong cancer susceptibility. Panzeri et al. use a Trim28+/D9 mouse model with intrinsic developmental heterogeneity to show that ‘heavy’ and ‘light’ developmental morphs exhibit different timing, type and severity of cancer, linked to a relevant DNA hypomethylation signature.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"6 2","pages":"385-403"},"PeriodicalIF":28.5000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s43018-024-00900-3.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cancer","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s43018-024-00900-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Mutations in cancer risk genes increase susceptibility, but not all carriers develop cancer. Indeed, while DNA mutations are necessary drivers of cancer, only a small subset of mutated cells go on to cause the disease. To date, the mechanisms underlying individual cancer susceptibility remain unclear. Here, we took advantage of a unique mouse model of intrinsic developmental heterogeneity (Trim28+/D9) to investigate whether early-life epigenetic variation influences cancer susceptibility later in life. We found that heterozygosity of Trim28 is sufficient to generate two distinct early-life epigenetic states associated with differing cancer susceptibility. These developmentally primed states exhibit differential methylation patterns at typically silenced heterochromatin, detectable as early as 10 days of age. The differentially methylated loci are enriched for genes with known oncogenic potential, frequently mutated in human cancers and correlated with poor prognosis. This study provides genetic evidence that intrinsic developmental heterogeneity can prime individual, lifelong cancer susceptibility. Panzeri et al. use a Trim28+/D9 mouse model with intrinsic developmental heterogeneity to show that ‘heavy’ and ‘light’ developmental morphs exhibit different timing, type and severity of cancer, linked to a relevant DNA hypomethylation signature.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
TRIM28依赖的发育异质性通过不同的表观遗传状态决定癌症易感性。
癌症风险基因的突变增加了易感性,但并非所有携带者都会患上癌症。的确,虽然DNA突变是癌症的必要驱动因素,但只有一小部分突变细胞会导致癌症。迄今为止,个体癌症易感性的潜在机制仍不清楚。在这里,我们利用一种独特的小鼠内在发育异质性模型(Trim28+/D9)来研究生命早期表观遗传变异是否会影响生命后期的癌症易感性。我们发现Trim28的杂合性足以产生与不同癌症易感性相关的两种不同的早期表观遗传状态。这些发育启动状态在通常沉默的异染色质上表现出不同的甲基化模式,早在10天大时就可以检测到。差异甲基化位点富含已知致癌潜力的基因,在人类癌症中经常发生突变,并与不良预后相关。这项研究提供了遗传证据,内在的发育异质性可以启动个体,终身癌症易感性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nature cancer
Nature cancer Medicine-Oncology
CiteScore
31.10
自引率
1.80%
发文量
129
期刊介绍: Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.
期刊最新文献
The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations. Erythrocyte-antibody conjugates to overcome immunotherapy resistance. Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection. Setting higher standards for reports of microbial species in human cancers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1